Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zidebactam
- Development stage
- Phase 1
- Lead developer
- Wockhardt
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Zidebactam is a novel small molecule beta-lactamase inhibitor and antibiotic adjuvant developed to combat serious infections caused by highly drug-resistant Gram-negative bacteria. It belongs to the bicyclo-acyl hydrazide (BCH) group, which is derived from diazabicyclooctanes (DBOs). Zidebactam acts as a dual-action agent by binding with high affinity to Penicillin-binding protein 2 (PBP2) and inhibiting class A and C beta-lactamases. This mechanism prevents the hydrolysis of partner antibiotics such as cefepime, thereby enhancing their antimicrobial activity. Zidebactam is primarily being developed in combination with cefepime for the treatment of complicated urinary tract infections, intra-abdominal infections, respiratory tract infections, neutropenic fever, and particularly for combating carbapenem-resistant Enterobacteriaceae and *Pseudomonas aeruginosa*.
- Other names
- zidebactam
02
Targets
Class A BL (Class A beta-lactamase)PBP2 (Penicillin-binding protein 2)AmpC (AmpC beta-lactamase)
Beyond the preview
Go deeper on zidebactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zidebactam.